On ECHEMI
Home > Drugs > Hengcheng Pharmaceutical Group Huainan Co., Ltd.
Hengcheng Pharmaceutical Group Huainan Co., Ltd.
  • Founded in:

    1998-10-14
  • Country:

    China China
  • Address:

    No. 1, Zhenxing Road, Economic and Technological Development Zone, Huainan City, Anhui Province
  • Tax NO.:

    913404007110463982
  • Registered Funds:

    66 million yuan
  • Website:

  • Email:

Related Drugs
Ibuprofen tablets
Each tablet of this product contains 0.1g of ibuprofen. The auxiliary materials are: hydroxypropyl cellulose, pregelatinized starch, dextrin, starch, silicon dioxide, magnesium stearate, sodium carboxymethyl starch, sucrose, talc, gelatin, silicone oil, and insect wax.
Name Description Content CAS NO. Registered Holders
Ibuprofen

It has analgesic, anti-inflammatory and antipyretic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase, thereby alleviating tissue congestion and swelling caused by prostaglandins and reducing the sensitivity of peripheral nerve pain. It has an antipyretic effect through the hypothalamic temperature regulation center.

More

It has analgesic, anti-inflammatory and antipyretic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase, thereby alleviating tissue congestion and swelling caused by prostaglandins and reducing the sensitivity of peripheral nerve pain. It has an antipyretic effect through the hypothalamic temperature regulation center.

0.1g 15687-27-1 53
aspirin
Name Description Content CAS NO. Registered Holders
Acetylsalicylic acid

Extract from the above information

More

Extract from the above information

50-78-2 35
Chlorpheniramine Maleate Tablets
Each tablet of this product contains the main ingredient chlorpheniramine maleate 4 mg Chemical name: Chlorpheniramine maleate Molecular formula: C20H23ClN2O4 Molecular weight: 390.87
Name Description Content CAS NO. Registered Holders
Chlorphenamine maleate

As a histamine H1 receptor antagonist, this product can counteract capillary dilation caused by allergic reactions, reduce capillary permeability, and relieve wheezing caused by bronchial smooth muscle contraction. This product has a long-lasting antihistamine effect and also has a significant central inhibitory effect, which can increase the effects of anesthetics, analgesics, hypnotics and local anesthetics. This product is mainly metabolized in the liver.

More

As a histamine H1 receptor antagonist, this product can counteract capillary dilation caused by allergic reactions, reduce capillary permeability, and relieve wheezing caused by bronchial smooth muscle contraction. This product has a long-lasting antihistamine effect and also has a significant central inhibitory effect, which can increase the effects of anesthetics, analgesics, hypnotics and local anesthetics. This product is mainly metabolized in the liver.

4mg 113-92-8 28
Mesalazine
Name Description Content CAS NO. Registered Holders
5-Aminosalicylic acid

Extract from the above information

More

Extract from the above information

89-57-6 68
Mesalazine Enteric-coated Tablets
The main ingredient of this product is mesalazine. Its chemical name is 2-hydroxy-5-aminobenzoic acid. Its chemical structure is: Molecular formula: C7H7NO3 Molecular weight: 153.14
Name Description Content CAS NO. Registered Holders
5-Aminosalicylic acid

Mesalazine is the main active ingredient of sulfasalazine, which is used to treat ulcerative colitis. It may produce its effects mainly through local rather than systemic effects. In patients with chronic inflammatory bowel disease, the production of arachidonic acid metabolites in the local mucosa can be increased through the cyclooxygenase pathway and the lipoxygenase pathway, and mesalazine may reduce local inflammation by inhibiting the production of cyclooxygenase and prostaglandins in the colon.

More

Mesalazine is the main active ingredient of sulfasalazine, which is used to treat ulcerative colitis. It may produce its effects mainly through local rather than systemic effects. In patients with chronic inflammatory bowel disease, the production of arachidonic acid metabolites in the local mucosa can be increased through the cyclooxygenase pathway and the lipoxygenase pathway, and mesalazine may reduce local inflammation by inhibiting the production of cyclooxygenase and prostaglandins in the colon.

89-57-6 68
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.